Nelson Vergel founded the men’s health forum www.ExcelMale.com and www.DiscountedLabs.com, interviews experts and debunks myths about testosterone and other hormones that affect men’s health. ExcelMale.com is one of the largest and best moderated men’s health and TRT forums on the Internet, focused on increasing health, potency, and productivity in men considering or using TRT and other hormone therapies. With over 44,000 members that include educated men, physicians, pharmacists, dietitians, exercise trainers, nutritional supplement experts, and other professionals in the field, ExcelMale is quickly becoming a leader in the field . Forum topics range from testosterone replacement therapy (TRT), Trimix injections for ED, HCG use for better fertility and libido, estradiol management, thyroid function optimization, peptide information, exercise routines, best supplements for men, effective diets, TRT side effect management, and much more. We also provide men’s health information via interviews with experts, videos, and webinars. Last but not least, ExcelMale forum members can participate in blood test discussions and provide their reviews of TRT clinics and doctors, compounding pharmacies, pharmaceutical products, supplements, and much more. ExcelMale moderators review every post daily to detect spammers or abuse, so ExcelMale is a safe environment for all men. And since every man wants to help important women in their lives, the forum does not neglect female health information as we include a folder called “ExcelFemale” to post the latest on HRT in women.
Nelson Vergel Beyond Testosterone Podcast
Claim This Podcastby Nelson Vergel
Podcast Overview
Nelson Vergel founded the men’s health forum www.ExcelMale.com and www.DiscountedLabs.com, interviews experts and debunks myths about testosterone and other hormones that affect men’s health. ExcelMale.com is one of the largest and best moderated men’s health and TRT forums on the Internet, focused on increasing health, potency, and productivity in men considering or using TRT and other hormone therapies. With over 44,000 members that include educated men, physicians, pharmacists, dietitians, exercise trainers, nutritional supplement experts, and other professionals in the field, ExcelMale is quickly becoming a leader in the field . Forum topics range from testosterone replacement therapy (TRT), Trimix injections for ED, HCG use for better fertility and libido, estradiol management, thyroid function optimization, peptide information, exercise routines, best supplements for men, effective diets, TRT side effect management, and much more. We also provide men’s health information via interviews with experts, videos, and webinars. Last but not least, ExcelMale forum members can participate in blood test discussions and provide their reviews of TRT clinics and doctors, compounding pharmacies, pharmaceutical products, supplements, and much more. ExcelMale moderators review every post daily to detect spammers or abuse, so ExcelMale is a safe environment for all men. And since every man wants to help important women in their lives, the forum does not neglect female health information as we include a folder called “ExcelFemale” to post the latest on HRT in women.
Language
🇺🇲
Publishing Since
3/11/2021
Reach the team behind Nelson Vergel Beyond Testosterone Podcast
Verified contact details for this show aren't on file yet — sign up to get notified when they land.
Recent Episodes
May 6, 2026
The Weight Training Myths That Science Just Put to Rest
The ACSM just reviewed 137 studies and 30,000 people to update their weight training guidelines for the first time in 17 years — and the headline finding is wild: the 8–12 rep rule that everyone’s been following is a myth. You can build just as much muscle with lighter weights and higher reps, as long as you push close to fatigue. Equipment? Doesn’t matter. Complex programming? Unnecessary. Even 20 minutes, twice a week, moves the needle. Which ”rule” are you most glad to finally ditch?
May 2, 2026
Ibogaine and the Brain Factory
This podcast episode discuss ibogaine, a psychoactive alkaloid derived from African plants that shows significant potential for treating addiction, PTSD, and traumatic brain injuries. Unlike traditional maintenance drugs, ibogaine acts as a ”neurological reboot” by interrupting withdrawal symptoms and fostering deep psychological introspection. Recent clinical research, specifically the Stanford MISTIC protocol, demonstrates that co-administering magnesium can mitigate the substance’s primary risk of cardiac toxicity. Advanced neuroimaging indicates that the treatment facilitates a ”posterior shift” in brain waves, allowing the mind to release rigid trauma loops and repair damaged neural circuits. While it remains a Schedule I substance in the United States, recent federal executive orders and state-funded initiatives in Texas are accelerating the development of pharmaceutical analogs. These synthetic versions aim to preserve the medicine’s restorative benefits while eliminating its long hallucinogenic duration and heart risks. #ibogaine #psychedelic
January 11, 2026
The Psychedelic Medicine Pipeline 2026: Setbacks and Progress
The psychedelic therapeutics field has reached a pivotal moment in early 2026, marked by Compass Pathways achieving the first positive Phase 3 psilocybin results for treatment-resistant depression (3.6-point MADRS improvement, p＜0.001) while the industry recalibrates following the FDA’s August 2024 rejection of Lykos’ MDMA therapy for PTSD due to trial design concerns. Six compounds now hold Breakthrough Therapy Designation, with the most advanced programs including MindMed’s MM-120 LSD (four Phase 3 trials underway for anxiety and depression), Cybin’s CYB003 psilocybin (Phase 3 with 71% 12-month remission in Phase 2), and Transcend’s methylone TSND-201 emerging as a non-hallucinogenic PTSD alternative. The 5-MeO-DMT space is heating up with GH Research’s GH001 showing 57.5% remission and AtaiBeckley’s BPL-003 receiving BTD, while AbbVie’s $1.2 billion acquisition of Gilgamesh’s bretisilocin validates big pharma interest. Spravato’s expanded monotherapy approval and novel oral ketamine formulations (Tasman’s R-107 for at-home use) continue advancing, and a potential FDA policy shift toward single-trial approvals could accelerate timelines—with Compass, MindMed, and Cybin all potentially reaching FDA decisions by late 2026 or 2027.
36 total episodes available
Recent guests on Nelson Vergel Beyond Testosterone Podcast
Guests from recent episodes — sign up to see every guest that has ever appeared on this show.
Dr Jennifer Casperson
Guest
Dr [Guest Name]
Guest
FDA experts
Guest
Dr [Guest Name Credential]
Guest
Dr Bhasin
Guest
Dr John Smith
Guest
Similar Podcasts
Discover related shows you might enjoy
The Hunter Williams Podcast
Hunter Williams
The Peptide Podcast
The Peptide Queen
Peptide of The Week
JD Denham and Will Haas
Think BIG Bodybuilding
Think BIG Bodybuilding Media
Muscle Intelligence
Ben Pakulski
The Dr. Gabrielle Lyon Show
Dr. Gabrielle Lyon
Peptalk: Peptides Unpacked
Dr. Kylie Burton & Jessica Briecke
Mind Pump: Raw Fitness Truth
Sal Di Stefano, Adam Schafer, Justin Andrews, Doug Egge
The Peter Attia Drive
Peter Attia, MD
unPAUSED with Dr. Mary Claire Haver
Audacy | Mary Claire Haver, MD
RP Strength Podcast
Nick Shaw
TRT DAD
TRT DAD
The Revive Stronger Podcast
Revive Stronger
TRT Talks
Thrivelab
Vigorous Steve Podcast
Vigorous Steve
Deep-dive analytics for Nelson Vergel Beyond Testosterone Podcast
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is Nelson Vergel Beyond Testosterone Podcast?
- How often does this podcast release new episodes?
This podcast updates daily.
- Where can I listen to this podcast?
This podcast is available on 4 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
Information about guest appearances is not available.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.